Cerep has announced the signature of a three-year collaboration agreement with Servier. The terms of the agreement provide that Servier will identify targets of interest and will transfer to Cerep its collection of compounds. Cerep will be responsible for the development and validation of the corresponding pharmacological assays and will run high throughput screenings on Servier library.
As part of this agreement, Cerep will also profile hit compounds identified during the high throughput screening campaigns as well as the drug candidates optimized for the selected target. Screening and profiling data will be made available in real time through the secured web access system Data OnLine developed by Cerep.
In addition, Servier will have access to BioPrint services for an improved interpretation of in vitro data and for a better selection of drug candidates with less potential side effects and optimised safety profile. Financial terms of the agreement are undisclosed but include a monthly payment during the 3 years of the collaboration.
On 15th June Cerep announced a Cerep announced a kinase profiling agreement with Eli Lilly.
